Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 (Galcanezumab) in Japanese Patients With Episodic Migraine

NCT02959177 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT02959177
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02959177 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 (Galcanezumab) in Japanese Patients With Episodic Migraine
Lead sponsor
Eli Lilly and Company
Phase
Phase 2
Overall status
Completed
Start date
November 9, 2016
Completion date
January 18, 2019
Enrollment
459 (actual)
Sites
47

Conditions

As the registry lists them; a condition with its own page is linked.

migraine